- Home
- WRBY vs NVCR Comparison
WRBY vs NVCR Comparison
Compare WRBY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- NVCR
- Stock Information
- Founded
- WRBY 2010
- NVCR 2000
- Country
- WRBY United States
- NVCR Jersey
- Employees
- WRBY N/A
- NVCR N/A
- Industry
- WRBY Ophthalmic Goods
- NVCR Medical/Dental Instruments
- Sector
- WRBY Health Care
- NVCR Health Care
- Exchange
- WRBY Nasdaq
- NVCR Nasdaq
- Market Cap
- WRBY 1.9B
- NVCR 1.8B
- IPO Year
- WRBY 2021
- NVCR 2015
- Fundamental
- Price
- WRBY $17.23
- NVCR $17.39
- Analyst Decision
- WRBY Buy
- NVCR Buy
- Analyst Count
- WRBY 8
- NVCR 5
- Target Price
- WRBY $16.88
- NVCR $26.60
- AVG Volume (30 Days)
- WRBY 1.4M
- NVCR 1.3M
- Earning Date
- WRBY 11-07-2024
- NVCR 10-30-2024
- Dividend Yield
- WRBY N/A
- NVCR N/A
- EPS Growth
- WRBY N/A
- NVCR N/A
- EPS
- WRBY N/A
- NVCR N/A
- Revenue
- WRBY $719,929,000.00
- NVCR $549,964,000.00
- Revenue This Year
- WRBY $15.94
- NVCR $16.23
- Revenue Next Year
- WRBY $13.07
- NVCR $6.09
- P/E Ratio
- WRBY N/A
- NVCR N/A
- Revenue Growth
- WRBY 13.67
- NVCR 8.33
- 52 Week Low
- WRBY $9.83
- NVCR $10.87
- 52 Week High
- WRBY $18.37
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- WRBY 57.79
- NVCR 43.24
- Support Level
- WRBY $16.71
- NVCR $15.61
- Resistance Level
- WRBY $17.86
- NVCR $17.31
- Average True Range (ATR)
- WRBY 0.66
- NVCR 1.29
- MACD
- WRBY 0.01
- NVCR 0.05
- Stochastic Oscillator
- WRBY 62.77
- NVCR 11.59
About WRBY Warby Parker Inc.
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.